Uddrag fra investing.com:
Shares in Novo Nordisk (CSE:NOVOb) climbed more than 6% on Thursday after the U.S. Food and Drug Administration proposed restricting the compounding of weight-loss medications.
The FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulks list, stating there is no clinical need for outsourcing facilities to compound these drugs.
A trader described the development as positive for the Danish drugmaker.
The regulatory agency has opened a comment period running until June 29, 2026, before making a final determination on the proposal.
Novo Nordisk reached its highest level in more than two months on Thursday and was the top gainer on the Copenhagen stock exchange.
The stock has declined more than 16% year-to-date.
